Research disclosures for Dr. Gregory Poland
Updated 8/1/2022

Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland gives consultative advice to AiZtech; AstraZeneca UK Limited; Eli Lilly and Company; Emergent Biosolutions; Exelixis, Inc.; Genevant Sciences, Inc.; GlaxoSmithKline; Janssen Global Services, LLC; Medicago USA; Merck & Co. Inc.; Moderna; Novavax; Pfizer-BNT; Regeneron Pharmaceuticals, Inc.; Syneos Health; Valneva and Vyriad. Dr. Poland holds patents related to vaccinia, influenza, and measles peptide vaccines. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.